Short interest in Infinity Pharmaceuticals Inc (OTC:INFIQ) decreased during the last reporting period, falling from 744.83K to 744.83K. This put 0.83% of the company's publicly available shares short.

Infinity Pharmaceuticals will be releasing earnings Q3 on November 14. Analysts predict Infinity Pharmaceuticals will release losses per share of $0.120. Go here to follow Infinity Pharmaceuticals ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Infinity shares get a temporary boost after presenting a copious amount of preclinical and clinical data at the American Society of Hematology's annual meeting. Although we don't believe in timing the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity”) today announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P. (“BVF”), Infinity ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...

A Massachusetts biotech is clearing out its C-suite in the wake of a failed merger agreement that had already cost 21 jobs. Infinity Pharmaceuticals Inc. (Nasdaq: INFI) CEO Adelene Perkins, chief ...

Disappointing results from a clinical trial cause traders to head for the exits. The results showed that duvelisib was able to meet its primary endpoint, demonstrating an overall response rate of 46%.

- MARIO-4 registration study in frontline metastatic triple negative breast cancer to be initiated by year end 2022 - - MARIO-P platform study in multiple solid tumors to be initiated on a rolling ...

Encouraging Topline Data From Phase 1 Study of IPI-940 Reported Decision Demonstrates Strength of Alliance and Underscores Complementary Capabilities of the Partners CAMBRIDGE, Mass., Oct. 26, 2010 ...

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage ...